Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer:: European organization of research and treatment of cancer gastrointestinal group study 40952

Purpose: This trial was conducted to determine whether high-dose fluorouracil (FU) given as a weekly 24-hour infusion is more active than bolus FU + leucovorin (LV), and whether high-dose infusional FU can be modulated by LV. Patients and Methods: A total of 497 patients with previously untreated metastatic colorectal cancer were randomly assigned to receive bolus FU 425 mg/m(2) intravenously + LV 20 mg/m(2) on days 1 to 5 and repeated on day 28 (FU + LV), or FU 2,600 mg/m(2) as a 24-hour infusion alone (FU24h) or in combination with 500 mg/m(2) LV (FU24h + LV)-all given weekly x6 followed by a 2-week rest period. Survival was the major study end point. Results: With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% Cl, 10.2 to 15.0 months]; FU24h, 13.0 months [95% Cl, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% Cl, 12.0 to 16.4 months]; P = .724). Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% Cl, 3.4 to 4.9]; FU24h, 4.1 months [95% Cl, 3.4 to 5.0]; FU24h + LV 5.6 months [95% Cl, 4.4 to 6.7]; P = .029). The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant). Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms; however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm. Global quality of life did not differ within the three arms. Conclusion: Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV. Leucovorin increases PFS if added to FU24h, but increases toxicity. (C) 2003 by American Society of Clinical Oncology.